Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Fuji Pharma/M3’s Dysmenorrhea Drug Filed in Japan, 2024 Rollout Targeted
October 19, 2023
- Herceptin Biosimilars Get Colorectal Cancer Nod: Celltrion, Nippon Kayaku
October 19, 2023
- Daiichi Sankyo Ordered to Pay 8% Royalty to Seagen in ADC Patent Row
October 19, 2023
- BMS Looks to Double Japan Biz in Next 10 Years with Partnership as a Pillar
October 19, 2023
- Broader Use of Blood Biomarkers Key to Maximizing Leqembi’s Value: Eisai Exec
October 18, 2023
- IBM Leads Development of Integrated Drug Supply Database for Wholesaler Reps, Pharmacists
October 18, 2023
- Guardant Liquid Biopsy Test Approved as CDx for Targeted Colorectal Cancer Drugs
October 17, 2023
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Meiji/KM’s XBB.1.5-Tailored COVID Jab to Enter Pediatric PIII Study
October 17, 2023
- EU Panel Backs Astellas’ Hot Flash Drug
October 17, 2023
- Oral Flu Drug Prescriptions 17 Times Higher than Pre-COVID: September Survey
October 16, 2023
- Japan Pharma Market to Contract after 2027 on Biosimilar Influx: Fuji Keizai
October 13, 2023
- Shonan iPark Looks to Woo Korean Firms by Partnering with Govt: Chief
October 13, 2023
- Viatris to Discontinue 28 APIs/48 Products for Supply, Productivity Reasons
October 12, 2023
- Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
October 12, 2023
- Astellas, Shared Lab Operators Link Up on Life Science Ecosystem
October 12, 2023
- Donanemab’s Limited Duration of Dosing Benefits Patients on Safety Front: Lilly CSO
October 11, 2023
- Japan Ethical Drug Sales Surge 8.1% in August: Crecon
October 10, 2023
- Kyowa Kirin to Acquire Orchard to Forge Ahead in Gene Therapy
October 6, 2023
- Hyperhidrosis Drug Ecclock Filed in South Korea: Kaken
October 6, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…